A warning sign Professor Victoria Sanz-Moreno, Professor of Cancer Cell and Metastasis Biology at The Institute of Cancer Research, London, who led the study said: Our study has helped us to better understand how some cancer cells protect themselves from the stresses they encounter as they attempt to spread around the body
to evaluate the potential effect of TZT on the biomarkers of non-alcoholic steatohepatitis in T2DM patients showed that TZT treatment increases adiponectin and reduces related inflammation in T2DM patients
Often seen, rarely recognized: mast cell activation diseasea guide to diagnosis and therapeutic options
Human sleep studies were conducted mainly during the 1980s and early 1990s, but they involved small groups, inconsistent methods and mixed results
Considering that GLP-1R agonists are FDA approved drugs to treat T2DM and also ameliorate NASH, in the present study we evaluated the efficacy of a GLP-1R agonist in two mouse models: one model with NASH-like features (methionine and choline-deficient (MCD) diet), and a second high-fat model of metabolic syndrome and hepatic dysfunction
Willemen, M